FCGR3A and systemic lupus erythematosus: The degree of reduction in the FcγRIIIA-stimulating activity of U1RNP-containing ICs by RNase treatment differed among patients, with an almost complete loss observed in 2 patients with MCTD or SLE and only a slight reduction observed in the other 2 patients (Figure 4A).